ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3064

Cardiac Manifestation of  Takayasu  Arteritis

Jin Wan, rheumatology and immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease, clinical research and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To explore cardiac manifestation of Takayasu arteritis and independent risk factor.

Methods: We retrospectively analyzed manifestations and helpful tests in 55 TA patients.  

Results: Fifty-five patients(55/85,64.7%)with TA complicated by cardiac involvement were seen over 10 years£®The male to female ratio was l©U5.87, and the mean age at onset of TA was 24 years. There was no statistically significant difference between TA with and without cardiac involvement groups in terms of gender,clinical type,cardiac symptoms, except confirmed diagnosis time[36(9,168)months vs 12(6,24)months, P=0.001], chest pain[27.3%(15/55)vs 6.7%(2/30),P=0.023]and blood pressure difference >10 mmHg between right-to-left sides[69.1%(38/55) vs 46.7%(14/30),P=0.043]. Cardiac disease included hypertensive heart disease (30 patients,54.5%),cardiomyopathy(6 patients,10.9%),valvular disease(36 patients,65.5%),coronary artery disease(9 patients,16.4%),and pulmonary hypertension (7 patients,12.7%)£®At onset age in patients renal artery involvement was significantly younger in hypertensive heart disease[(28±14)years vs(44±14)years,P=0.006]. LVEF[(34±8)% vs(66±7)%, P=0.000]and age at onset [(15±13)years vs(25±11)years, P=0.030] were statistically significant between patients in TA with and without cardiomyopathy. Multivariate analysis showed that higher CRP was independent risk factor for pulmonary hypertension(OR=0.082,95%CI:0.007-0.965,P=0.047),mitral valve regurgitation(OR=0.192,95%CI:0.040-0.929,P=0.031)and tricuspid regurgitation(OR=0.093,95%CI:0.011-0.761,P=0.018).

Conclusion: We should pay attention to cardiac manifestation of Takayasu’s Arteritis complicated by cardiac involvement to improve its early diagnosis.


Disclosure: J. Wan, None;

To cite this abstract in AMA style:

Wan J. Cardiac Manifestation of  Takayasu  Arteritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cardiac-manifestation-of-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiac-manifestation-of-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology